Stock Events

Stock Events

OmniAb

0

23

+$0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

6AugExpected

Q3 2024

Q4 2024

Q2 2025

Q3 2025

Q1 2026

Q2 2026

-0.16

-0.13

-0.09

-0.06

Expected EPS

-0.12

Actual EPS

N/A

Financials

-235.05%Profit Margin

Unprofitable

2021

2022

2023

2024

52.78MRevenue

-124.07MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.

Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.

Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.

Gilead Sciences

Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.

Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.

Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.

AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.

Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.

Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Show more...

CEO

Matthew W. Foehr

Employees

89

Country

United States

Listings

0 Comments

Share your thoughts

FAQ

What is OmniAb stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange OmniAb stocks are traded under the ticker OABI V.

What is OmniAb revenue for the last year?▼

OmniAb revenue for the last year amounts to 52.78M USD.

What is OmniAb net income for the last year?▼

OABI V net income for the last year is -124.07M USD.

How many employees does OmniAb have?▼

As of August 17, 2026, the company has 89 employees.

In which sector is OmniAb located?▼

OmniAb operates in the Health & Wellness sector.

When did OmniAb complete a stock split?▼

OmniAb has not had any recent stock splits.

Where is OmniAb headquartered?▼

OmniAb is headquartered in EMERYVILLE, United States.